Denosumab Versus Risedronate in Glucocorticoid‐Induced Osteoporosis: Final Results of a Twenty‐Four–Month Randomized, Double‐Blind, Double‐Dummy Trial

Objective Clinical trial results have shown that, in glucocorticoid‐treated patients, treatment with denosumab 60 mg subcutaneously once every 6 months (Q6M) increased spine and hip bone mineral density (BMD) at month 12 significantly more than treatment with risedronate 5 mg orally once daily (QD)....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2019-07, Vol.71 (7), p.1174-1184
Hauptverfasser:	Saag, Kenneth G., Pannacciulli, Nicola, Geusens, Piet, Adachi, Jonathan D., Messina, Osvaldo D., Morales‐Torres, Jorge, Emkey, Ronald, Butler, Peter W., Yin, Xiang, Lems, Willem F.
Format:	Artikel
Sprache:	eng
Schlagworte:	Absorptiometry, Photon Aged Biocompatibility Bisphosphonates Bone Density Bone Density Conservation Agents - therapeutic use Bone mineral density Bone Remodeling Calcium Collagen Type I - metabolism Denosumab - therapeutic use Double-Blind Method Double-blind studies Female Femur Neck - diagnostic imaging Fractures Glucocorticoids Glucocorticoids - adverse effects Hip Hip - diagnostic imaging Humans Immunotherapy Lumbar Vertebrae - diagnostic imaging Male Middle Aged Monoclonal antibodies Original Osteoporosis Osteoporosis - chemically induced Osteoporosis - drug therapy Osteoporosis - metabolism Osteoporotic Fractures - prevention & control Patients Peptide Fragments - metabolism Peptides - metabolism Prednisone Procollagen - metabolism Randomization Risedronic acid Risedronic Acid - therapeutic use Safety Spine Spine (lumbar) Surgical implants Treatment Outcome Vitamin D
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!